Screener / SEC EDGAR /CIK 0001504776 /10-K filed Feb 26, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Eye Care

Warby Parker Inc. WRBY

Compare with peers Embed
FY2025 at a glance

Sales up 13.0%, free cash flow up to $43.7M

XBRL, from each 10-K
RevenueStatements
$871.9M from $771.3M in FY2024
FY2019FY2025
Net incomeStatements
$1.6M from -$20.4M in FY2024
FY2019FY2025
Free cash flowStatements
$43.7M from $34.7M in FY2024
FY2019FY2025
EPS (diluted)Statements
$0.01 from $-0.17 in FY2024
FY2019FY2025
Operating marginStatements
-0.6% from -3.9% in FY2024
FY2019FY2025

The latest figures

Price and key numbers

From EDGAR
All key numbers (40)
EPS (ttm)
0.06
Sales (ttm)
934.7M
Net income (ttm)
7.5M
Sales growth
+13.0%
EPS growth
-
Sales Q/Q
+10.4%
Free cash flow
21.3M
Gross margin
54.7%
Oper. margin
0.2%
Net margin
0.8%
FCF margin
2.3%
ROE
1.9%
ROA
0.9%
R&D / sales
-
Dividend
-
Debt/Eq
-
Curr. ratio
2.26
Cash
287.9M
Op. cash flow (ttm)
102.1M
EBITDA
44.9M
EBITDA margin
5.2%
Quick ratio
1.98
Interest cover
-16.42
ROIC
-0.7%
FCF after stock pay
9.2M
Oper. margin low 5y
-26.6%
Tax rate
46.1%
Stock pay / sales
4.0%
Shares out.
126.1M
Shares Y/Y
+3.9%
Book / share
3.20
Cash / share
2.28
Sales / share
7.41
Asset turnover
1.18
Inventory turns
9.02
Days sales out.
1
Sales 3Y CAGR
+13.4%
Sales 5Y CAGR
+17.2%
Employees
4,036
Sales / employee
232K

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Revenue and net income, FY2019 to FY2025

Each fiscal year from its own 10-K · XBRL

Revenue 871.9M +15.3% a year Net income 1.6M
FY2019 revenue 370.5M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001504776-22-000007 FY2019 net income 0 · NetIncomeLoss, 0001504776-22-000007 370.5M FY2019 FY2020 revenue 393.7M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001504776-23-000006 FY2020 net income -55.9M · NetIncomeLoss, 0001504776-23-000006 393.7M FY2020 FY2021 revenue 540.8M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001504776-24-000006 FY2021 net income -144.3M · NetIncomeLoss, 0001504776-24-000006 540.8M FY2021 FY2022 revenue 598.1M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001504776-25-000010 FY2022 net income -110.4M · NetIncomeLoss, 0001504776-25-000010 598.1M FY2022 FY2023 revenue 669.8M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001504776-26-000006 FY2023 net income -63.2M · NetIncomeLoss, 0001504776-26-000006 669.8M FY2023 FY2024 revenue 771.3M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001504776-26-000006 FY2024 net income -20.4M · NetIncomeLoss, 0001504776-26-000006 771.3M FY2024 FY2025 revenue 871.9M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001504776-26-000006 FY2025 net income 1.6M · NetIncomeLoss, 0001504776-26-000006 871.9M FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing. "A year" is the steady yearly growth from FY2019 to FY2025 (6 years).

Growth per share, FY2019 to FY2025

Earnings, book value and free cash flow for each diluted share · 10-K XBRL, every year linked to its filing

Average yearly growth
Book value per share -7.5% a year FY2021 $4.01 to FY2025 $2.94, 4 years
Free cash flow per share +7.9% a year FY2020 $0.24 to FY2025 $0.35, 5 years
Fiscal year toEPS (diluted)Book value / shareFree cash flow / share
Dec 31, 2025 $0.01$2.94$0.35
Dec 31, 2024 -$0.17$2.82$0.29
Dec 31, 2023 -$0.54$2.57$0.06
Dec 31, 2022 -$0.96$2.49-$0.43
Dec 31, 2021 -$2.21$4.01-$1.13
Dec 31, 2020 -$1.05-$3.74$0.24
Dec 31, 2019 -$1.10-$3.61-$0.21

Per share means per diluted weighted-average share of the same fiscal year (the count under diluted EPS, put on today's share count after a split). Book value is shareholders' equity at the year end, including any preferred stock; free cash flow is operating cash flow less capital spending. Each tile's rate is the steady yearly growth from the first to the last year it names: the window starts at the oldest year, up to ten years back, with a value above zero.

What the balance sheet holds, per share

Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used

Net current asset value, FY2025, in dollars
  • + Current assets $352.4M
  • − All liabilities $353.2M
  • = Net current asset value -$751K
Per share, year by year
Tangible book value, FY2025, in dollars
  • + Shareholders' equity $367.7M
  • = Tangible book value $367.7M
Per share, year by year

Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.

WRBY against Health care peers

Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.

Ten years, side by side
Sales growth
+4.8%+20.2%
+13.0%61st of 155 · median +10.5%
Net margin
-4.1%15.3%
0.8%104th of 154 · median 6.8%
Return on equity
-5.2%18.5%
1.9%96th of 144 · median 9.2%
Free cash flow margin
2.3%19.2%
2.3%109th of 145 · median 10.0%
WRBY and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthFYGross marginttmNet marginttmROEttmFCF marginttmDebt / equitylatest
WRBY Warby Parker Inc.$934.7M +13.0%54.7%0.8%1.9%2.3%-
CORT Corcept Therapeutics Inc$963.6M +12.8%-16.8%19.5%20.2%-
BCRX Biocryst Pharmaceuticals Inc$961.5M +94.1%97.8%-37.4%-38.0%-
IONS Ionis Pharmaceuticals Inc$960.1M +33.8%--56.9%-138.8%-64.2%4.60
BBIO BridgeBio Pharma, Inc.$945.5M +126%94.3%-62.6%--39.1%-
TGTX TG Therapeutics, Inc.$897.8M +87.3%82.7%11.8%18.5%9.5%1.30
All 162 companies in the group

Where each dollar goes

Revenue through the costs to the net profit, from the 10-K income statement and revenue by product

From $871.9M of sales to $1.6M of profit FY2025

  • Eyewear $719.1M
  • Contacts Products $97.2M
  • Eye care $55.7M
  • Shipping and Handling $3.7M
Revenue to Gross profit: $470.6MRevenue to Cost of revenue: $401.3MGross profit to Net profit: $1.6MGross profit to Costs, tax, other: $468.9M Revenue: $871.9M REVENUE $871.9M +13% Y/Y Gross profit: $470.6M · 54% margin GROSS PROFIT $470.6M 54% margin · +10% Y/Y Cost of revenue: $401.3M · 46% of revenue COST OF REVENUE $401.3M 46% of revenue Net profit: $1.6M · 0% margin NET PROFIT $1.6M 0% margin Costs, tax, other: $468.9M · 54% of revenue COSTS, TAX, OTHER $468.9M 54% of revenue

Band widths are the money. Gross profit is revenue less cost of revenue; operating expenses are gross profit less operating profit; R&D is from the income statement and the rest of the operating expenses is everything else; tax includes interest and other items when they are small. Y/Y is the change from the fiscal year before. The full income statement

Where the return on equity comes from

DuPont: net margin × asset turnover × leverage, FY2025 against FY2021 · 10-K XBRL, year-end balances

Return on equity 0.4% FY2021: -50.4% net income ÷ equity
Net margin 0.2% FY2021: -26.7% profit per $ of sales: 1.6M ÷ 871.9M
Asset turnover 1.21× FY2021: 1.23× sales per $ of assets: 871.9M ÷ 720.9M
Leverage 1.96× FY2021: 1.54× assets per $ of equity: 720.9M ÷ 367.7M

The three parts multiply to the return on equity. A higher return from leverage alone means more debt or less equity (buybacks shrink equity), not a better business. Year-end balances as filed, not averages, so each number is one line of one 10-K; hover a box for its XBRL tags.

Profitability

  • Net margin below the peer median
    0.8% vs 6.8%
  • Gross margin down over 5 years
    58.9% → 54.0%
  • Return on equity below 15%
    1.9%
  • A profit in 1 of 7 years
Net margin, FY2019 to FY2025: 0.0% to 0.2%

Balance sheet

  • Interest covered less than 5 times
    Operating income is -16.4× interest expense
  • Current assets cover current liabilities
    Current ratio 2.26

Cash and shareholders

  • Free cash flow positive in 4 of 7 years
    $43.7M last year
  • Share count up over 5 years
    +135.9%
  • Cash from operations above net income
    $110.8M vs $1.6M
Free cash flow, FY2019 to FY2025: -11.2M to 43.7M

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

Contracted revenue and deferred revenue

Backlog (remaining performance obligations) and cash received in advance, by balance sheet date · XBRL

Contract liabilities, current part

Paid in advance $21.5M cash received before delivery, not yet recognized as revenue, Sep 30, 2026 · -2.1% on a year earlier

Both are balance-sheet-date values from the 10-K and 10-Qs. Backlog is what is under contract, not a forecast: contracts can be cancelled or change in size, and a company counts them in its own way. Hover a number for its XBRL line; click it to open the filing.

Income statement, balance sheet and cash flow

Statements · XBRL, each 10-K and 10-Q

From EDGAR

WRBY's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 7. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Revenue871.9M
FY2019: 370.5MFY2020: 393.7MFY2021: 540.8MFY2022: 598.1MFY2023: 669.8MFY2024: 771.3MFY2025: 871.9M FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Net income1.6M
FY2019: 0FY2020: -55.9MFY2021: -144.3MFY2022: -110.4MFY2023: -63.2MFY2024: -20.4MFY2025: 1.6M FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Free cash flow43.7M
FY2019: -11.2MFY2020: 12.7MFY2021: -80.5MFY2022: -49.8MFY2023: 7.3MFY2024: 34.7MFY2025: 43.7M FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Free cash flow after stock pay9.2M
FY2019: -19.7MFY2020: -32.2MFY2021: -187.7MFY2022: -147.8MFY2023: -63.2MFY2024: -12.6MFY2025: 9.2M FY2019FY2020FY2021FY2022FY2023FY2024FY2025
EPS (diluted)0.01
FY2019: -1.10FY2020: -1.05FY2021: -2.21FY2022: -0.96FY2023: -0.54FY2024: -0.17FY2025: 0.01 FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Diluted shares125.1M
FY2019: 52.4MFY2020: 53.0MFY2021: 71.2MFY2022: 114.9MFY2023: 117.4MFY2024: 120.4MFY2025: 125.1M FY2019FY2020FY2021FY2022FY2023FY2024FY2025

Revenue by product or service

year to Dec 31, 2025
RevenueSharevs year before
Eyewear 719.1M82.5% +10.3%
Contacts Products 97.2M11.1% +23.4%
Eye care 55.7M6.4% +37.5%
Shipping and Handling 3.7M0.4% -2.6%

10-K 0001504776-26-000006, segment and revenue notes (XBRL).

Income statement

From EDGAR
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue370.5M393.7M540.8M598.1M669.8M771.3M871.9M
Cost of revenue147.4M161.8M223.0M257.1M304.5M344.5M401.3M
Gross profit223.1M231.9M317.7M341.1M365.2M426.8M470.6M
SG&A224.8M287.6M461.4M452.3M437.2M456.9M475.9M
Operating income-1.7M-55.6M-143.7M-111.2M-72.0M-30.1M-5.3M
Interest expense88K466K150K184K227K246K325K
Pretax income276K-55.7M-144.0M-109.9M-62.8M-19.5M3.0M
Income tax276K190K263K497K433K875K1.4M
Net income0-55.9M-144.3M-110.4M-63.2M-20.4M1.6M
EPS (diluted)-1.10-1.05-2.21-0.96-0.54-0.170.01
Diluted shares52.4M53.0M71.2M114.9M117.4M120.4M125.1M
Depreciation & amortization14.5M17.8M21.6M31.9M38.6M45.9M50.3M
EBITDA12.9M-37.9M-122.1M-79.3M-33.4M15.8M44.9M
Gross margin60.2%58.9%58.8%57.0%54.5%55.3%54.0%
Operating margin-0.4%-14.1%-26.6%-18.6%-10.7%-3.9%-0.6%
Net margin0.0%-14.2%-26.7%-18.5%-9.4%-2.6%0.2%
Revenue growth-+6.3%+37.4%+10.6%+12.0%+15.2%+13.0%

Cash flow

From EDGAR
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow21.4M32.8M-32.0M10.4M61.0M98.7M110.8M
Capital spending32.6M20.1M48.5M60.2M53.7M64.0M67.0M
Free cash flow-11.2M12.7M-80.5M-49.8M7.3M34.7M43.7M
Stock-based pay (added back)8.5M44.9M107.1M98.0M70.5M47.3M34.5M
Free cash flow after stock pay-19.7M-32.2M-187.7M-147.8M-63.2M-12.6M9.2M
Buybacks79.5M08.1M00--
Investing cash flow-32.6M-20.1M-48.5M-60.2M-54.7M-66.0M-67.0M
Financing cash flow-83.4M245.9M23.0M3.3M2.9M5.0M-12.0M

Stock-based pay and leases

From EDGAR
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)8.5M44.9M107.1M98.0M70.5M47.3M34.5M
Stock-based pay / revenue2.3%11.4%19.8%16.4%10.5%6.1%4.0%
Operating lease cost---25.8M30.1M34.9M38.5M
Right-of-use assets--0127.0M122.3M171.3M170.8M
Operating lease liabilities--146.2M173.4M174.5M225.4M233.1M

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Sources

Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.

Also

Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/WRBY/export.csv") into a cell.

Next:Peers in numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.